Table 3 -.
Univariate Kaplan-Meier log-rank analysis and multivariate Cox proportional hazards models for RFS for RPS, TS, and all patients within cohort.
| RFS | RPS | Multivariate HR (95% CI); P | TS | Multivariate HR (95% CI); P | All | Multivariate HR (95% CI); P |
|---|---|---|---|---|---|---|
| Factor | Univariate | Univariate | Univariate | |||
| Female gender | P < 0.01 | 0.59 (0.42–0.84); P < 0.01 | P = 0.76 | P < 0.01 | 0.67 (0.50–0.89); P < 0.01 | |
| Age older than 65 y | P = 0.04 | 1.43 (1.01–2.02); P = 0.04 | P = 0.73 | P < 0.01 | 1.42 (1.05–7.42); P = 0.02 | |
| Race | P = 0.73 | P = 0.58 | P = 0.29 | |||
| DM | P = 0.11 | P = 0.37 | P = 0.03 | 1.11 (0.76–1.63); P = 0.58 | ||
| CAD | P = 0.29 | P = 0.22 | P = 0.36 | |||
| Smoking history | P = 0.66 | P = 0.01 | 1.68 (0.88–3.18); P = 0.12 | P = 0.26 | ||
| Prior radiation | P = 0.28 | P < 0.01 | 0.89 (0.39–2.00); P = 0.77 | P = 0.07 | ||
| Known genetic syndrome | P = 0.94 | P = 0.18 | P = 0.08 | |||
| Sepsis | P < 0.01 | 3.05 (1.24–7.46); P = 0.02 | P = 0.87 | P < 0.01 | 3.28 (1.45–7.42); P < 0.01 | |
| Multifocal | P = 0.04 | P = 0.36 | P < 0.01 | 1.25 (0.81–1.93); P = 0.31 | ||
| Margin | P < 0.01 | P = 0.83 | P < 0.01 | |||
| R0 | Reference | Reference | Reference | |||
| R1 | 1.81 (1.23–2.67); P < 0.01 | 1.85 (1.34–2.55); P < 0.01 | ||||
| R2 | 1.99 (1.05–3.75); P = 0.03 | 2.41 (1.39–4.17); P < 0.01 | ||||
| Histology | P < 0.01 | P < 0.01 | P < 0.01 | |||
| UPS | Reference | Reference | Reference | |||
| Chondrosarcoma | 3.77 (0.80–17.65); P = 0.09 | 0.26 (0.03–2.00); P = 0.20 | 1.48 (0.43–5.15); P = 0.54 | |||
| Leiomyosarcoma | 0.97 (0.51–1.85); P = 0.92 | 0.65 (0.22–1.90); P = 0.43 | 0.92 (0.56–1.50); P = 0.74 | |||
| Liposarcoma | 0.66 (0.344–1.25); P = 0.20 | 0.35 (0.11–1.10); P = 0.07 | 0.73 (0.45–1.19); P = 0.21 | |||
| Myxofibrosarcoma | 0.00 (0.00–>100); P = 0.96 | <0.01 (<0.01–>100); P = 0.97 | 0.00 (0.00–>100); P = 0.95 | |||
| MPNST | 2.10 (0.22–19.95); P = 0.52 | 2.41 (1.00–5.77); P = 0.05 | 3.55 (1.34–9.41): P = 0.01 | |||
| PNET | 0.41 (0.05–3.39); P = 0.41 | 0.45 (0.06–3.42); P = 0.44 | 0.43 (0.10–1.87); P = 0.26 | |||
| Rhabdomyosarcoma | 2.10 (0.24–19.77); P = 0.52 | 1.15 (0.14–9.30); P = 0.90 | 1.21 (0.23–6.40); P = 0.83 | |||
| Angiosarcoma | 12.76 (1.40–>100); P = 0.2 | 1.23 (0.49–3.10); P = 0.67 | 3.28 (1.34–8.06); P = 0.01 | |||
| Sarcoma not otherwise specified | 1.20 (9.46–3.18); P = 0.71 | 0.73 (0.23–2.39); P = 0.62 | 1.21 (0.57–2.59); P = 0.62 | |||
| Small round cell tumors | 8.39 (0.82–85.6); P = 0.07 | 0.71 (0.09–5.42); P = 0.74 | 1.27 (0.27–6.00); P = 0.77 | |||
| Synovial sarcoma | 7.99 (2.86–22.33); P < 0.01 | 0.67 (0.27–1.67); P = 0.39 | 1.20 (0.60–2.40); P = 0.60 | |||
| Other | 0.54 (0.23–1.29); P = 0.17 | 0.24 (0.10–0.58); P < 0.01 | 0.45 (0.23–0.88); P = 0.02 | |||
| Grade––low versus high grade | P < 0.01 | 2.19 (1.39–3.47); P < 0.01 | P = 0.22 | P < 0.01 | 2.27 (1.45–3.57); P < 0.01 | |
| Tumor necrosis | P < 0.01 | 1.36 (0.89–2.09); P = 0.16 | P = 0.62 | P < 0.01 | 1.68 (1.13–2.51); P = 0.01 | |
| Nodal status | P = 0.13 | P = 0.16 | P = 0.01 | 2.18 (1.17–4.06); P = 0.01 | ||
| Neoadjuvant | P = 0.38 | P = 0.61 | P = 0.12 | |||
| Adjuvant | P = 0.67 | P = 0.88 | P < 0.01 | 0.92 (0.63–1.33); P = 0.64 | ||
| Obesity | P = 0.92 | P = 0.09 | P = 0.46 | |||
| Size >20 cm | P = 0.95 | P = 0.06 | P < 0.01 | 1.40 (0.91–2.16); P = 0.12 | ||
| Elevated NLR | P = 0.20 | P = 0.05 | P = 0.02 | 0.64 (0.43–0.97); P = 0.03 | ||
| Elevated PLR | P = 0.06 | P = 0.03 | 1.06 (0.59–1.93); P = 0.84 | P < 0.01 | 1.49 (0.98–2.27); P = 0.06 |
HR = hazard ratio; PNET = primitive neuroectodermal tumor